S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed advanced solid tumor or non-Hodgkin's lymphoma for which no curative options exist
Measurable or nonmeasurable disease

Patients with brain metastases who require corticosteroids or anticonvulsants must be on a stable or decreasing dose of corticosteroids and seizure free for 30 days prior to study entry

Patients with known brain metastases must have had brain irradiation (whole brain or gamma knife)

No untreated (non-irradiated) brain metastases

PATIENT CHARACTERISTICS:

Zubrod performance status 0-2
Absolute neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
Bilirubin normal
Creatinine normal OR creatinine clearance > 60 mL/min
Cardiac ejection fraction normal by echocardiogram or MUGA
Able to swallow enteral medications
No feeding tubes
No intractable nausea or vomiting
No gastrointestinal (GI) tract disease resulting in an inability to take oral medication
No current active hepatic or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones
No malabsorption syndrome
No requirement for IV alimentation
No uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or everolimus, including other quinazoline compounds, such as gefitinib and erlotinib, or other rapamycins, such as sirolimus and temsirolimus
No known HIV positivity

No concurrent uncontrolled illness, including, but not limited to, any of the following:

Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Myocardial infarction or cerebrovascular accident within the past 3 months
Uncontrolled diarrhea
Psychiatric illness or social situation that would preclude compliance with study requirements
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Willing to undergo pharmacokinetic (PK) sampling and blood collection for PK and correlative studies (for patients enrolled in part II)

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior therapy
No prior lapatinib or everolimus
No prior surgical procedures affecting absorption
More than 14 days since prior major surgery, chemotherapy (42 days for nitrosoureas or mitomycin C), or radiotherapy
More than 28 days since prior investigational agents
At least 7 days since prior and no concurrent CYP3A4 inhibitors
At least 14 days since prior and no concurrent CYP3A4 inducers
At least 14 days since prior and no concurrent herbal or dietary supplements

No concurrent chemotherapy, hormone therapy, radiotherapy, immunotherapy, live vaccines or any other anticancer therapy

Concurrent luteinizing hormone-releasing hormone agonists allowed
Concurrent bisphosphonates or epoetin alfa or its analogue allowed

No concurrent gastric H2 blockers (e.g., cimetidine, ranitidine, nizatidine, famotidine) or proton pump inhibitors (e.g., omeprazole, esomeprazole, rabeprazole, pantoprazole, or lansoprazole)

Antacids allowed provided they are not administered within 1 hour before and after lapatinib
No concurrent glucocorticoids or immunosuppressants